Solid Tumor CAR-T: Making Progress in Brain Cancer Available to Purchase

Abstract: Results from a recently completed phase I trial assessing IL-13Rα2–targeting CAR T cells in high-grade glioma—mainly recurrent glioblastoma—highlight this therapy’s potential, with 29 of 58 patients achieving stable disease or better. Meanwhile, preliminary findings from two other studies—one of a dual EGFR CAR-bearing and T-cell engager–producing therapy, the other of CAR T cells jointly aimed at IL-13Rα2 and EGFR—indicate that both approaches are safe, feasible, and can induce rapid radiographic responses.